Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05733013 · ClinicalTrials.gov registry record
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
A clinical trial of Thyroid Cancer and Thyroid, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05733013 is a study of Thyroid Cancer and Thyroid that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 100 participants, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05733013, a study of Thyroid Cancer and Thyroid, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.
Conditions Studied
Interventions
- OTHER Surveillance Visit
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-02-07 |
| Est. Completion | 2028-02-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05733013
The ClinicalTrials.gov registry entry for NCT05733013 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (64% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Surveillance Visit is the first listed.
NCT05733013 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05733013 about?
NCT05733013 is a clinical study titled "A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer". The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.
What is the current status of trial NCT05733013?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-02-07. Estimated completion is 2028-02-07.
What conditions does trial NCT05733013 study?
This clinical trial studies the following conditions: Thyroid Cancer, Thyroid, Refractory Thyroid Cancer.
What interventions are being tested in trial NCT05733013?
The interventions under investigation include: Surveillance Visit (OTHER).
Who is sponsoring clinical trial NCT05733013?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05733013 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.